deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT04194125

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Conditions Neuroendocrine Tumors
Interventions 177Lu-DOTATOC
Updated 10 times since 2020 Last updated: Nov 2, 2020 Started: Feb 1, 2019 Primary completion: Jun 30, 2021 Completion: Jan 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04194125, this PHASE2 trial focuses on Neuroendocrine Tumors and remains ongoing. Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshotRecruiting~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshotRecruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotRecruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotRecruiting~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshotRecruiting~Jan 2022 – ~Dec 2022 · 11 months · monthly snapshotRecruiting~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Dec 2022 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  5. Jan 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

▶ Show 5 earlier versions

  1. Oct 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  3. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Apr 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  5. Jan 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Maria Sklodowska-Curie National Research Institute of Oncology
  • Medical University of Warsaw
  • National Center for Research and Development, Poland
  • The Diagnostic and Therapeutic Center Gammed; Poland
  • University of Warmia and Mazury
Data source: University of Warmia and Mazury

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations